Skip to content

EV / EBITDA at other companies

HealthStream logo
HealthStreamHSTM
10.5×-4.4×
Huron Consulting Group logo
Huron Consulting GroupHURN
13.7×-1.5×
Doximity logo
DoximityDOCS
17.9×-27.0×
Solventum logo
SolventumSOLV
6.4×-8.8×
Workday, Inc. logo
Workday, Inc.WDAY
21.5×-47.5×
IQVIA logo
IQVIAIQV
12.1×-0.6×

Other financials

Income statement

See full
Revenue$34.8M+3.7%
Operating income$5.6M-35.8%
Net income$3.2M+11.1%
EPS (diluted)$12.50+4,708%

Balance sheet

See full
Cash & equivalents$2.5M+1.8%
Total debt$74.0M+26.2%
Total equity$13.5M-54.5%
Total assets$134.6M-0.5%

Cash flow

See full
Operating cash flow$7.2M+8.0%
CapEx$1.8M-38.6%
Free cash flow$5.3M+46.1%

Valuation

See full
Market cap$486.12M+31.8%
Enterprise value$557.59M+26.5%
P/E40.8×+20.5×
P/S3.5×+0.9×

Profitability

See full
Operating margin16.4%-8.2pp
Net margin8.6%-6.6pp
FCF margin12.6%+2.0pp

Returns & leverage

See full
Return on equity55.2%-9.3pp
Debt / equity5.5×+3.5×
Current ratio0.5×0.0×

Where this comes from

Calculated from National Research Corporation’s reported figures.

Based on the most recent quarter.

The official record: National Research Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about National Research Corporation's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is National Research Corporation's EV / EBITDA?
National Research Corporation (NRC) reported EV / EBITDA of 16.5× in Q4 2025.
How has National Research Corporation's EV / EBITDA changed year-over-year?
National Research Corporation's EV / EBITDA increased by 44.5% year-over-year, from 11.4× to 16.5×.
What is the long-term trend for National Research Corporation's EV / EBITDA?
Over 2 years (2023 to 2025), National Research Corporation's EV / EBITDA has grown at a -12.7% compound annual growth rate (CAGR), from 21.6× to 16.5×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.